<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776083</url>
  </required_header>
  <id_info>
    <org_study_id>174</org_study_id>
    <nct_id>NCT04776083</nct_id>
  </id_info>
  <brief_title>Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>Role of Radiotherapy to the Primary Lesion in Metastatic Non-small Cell Lung Cancer Patients After First Line Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      study the effect of radiotherapy to the primary lesion after first line systemic therapy in&#xD;
      metastatic non-small cell lung cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metastatic non-small cell lung cancer patients after receiving their first line systemic&#xD;
      therapy according to their genetic mutation will be randomized to follow up versus&#xD;
      radiotherapy to the primary lesion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2021</start_date>
  <completion_date type="Anticipated">October 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>six months</time_frame>
    <description>time from randomization till disease progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patients quality of life</measure>
    <time_frame>six months</time_frame>
    <description>using the European Organization for Research and Treatment of Cancer core quality of life questionnaire, the EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>six months</time_frame>
    <description>time from randomization till death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients toxicity</measure>
    <time_frame>six months</time_frame>
    <description>number of participants suffer of different toxicity grades according to Common toxicity criteria of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients pattern of failure</measure>
    <time_frame>six months</time_frame>
    <description>Number of Participants suffer of disease progression in the primary site vs other newly developed sites</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-Small Cell Carcinoma of Lung, TNM Stage 4</condition>
  <condition>Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>radiotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after first line systemic therapy, patients will receive radiotherapy to the primary lesion, hypo-fractionated regimen 45gy will be given over 15 fractions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no intervention arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>after first line systemic therapy, patients will be kept under follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>first line systemic therapy</intervention_name>
    <description>first line systemic therapy according to the genetic mutation 0f the patient</description>
    <arm_group_label>no intervention arm</arm_group_label>
    <arm_group_label>radiotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3D radiotherapy or IMRT</intervention_name>
    <description>Hypo-fractionated radiotherapy to the primary lesion</description>
    <arm_group_label>radiotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed histological diagnosis of NSCLC.&#xD;
&#xD;
          2. Stage IV disease.&#xD;
&#xD;
          3. Patients with P.S ≤ 2.&#xD;
&#xD;
          4. finished at least 4 cycles of platinum-based doublet chemotherapy if patient has no&#xD;
             diver mutation, or at least 3 months of anti-EGFR, Anti-ALK according to their driver&#xD;
             mutation with SD, PR or CR.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of prior irradiation to the lung.&#xD;
&#xD;
          2. residual Malignant pleural or pericardial effusion at randomization time.&#xD;
&#xD;
          3. History of prior malignant tumor likely to interfere with the treatment protocol.&#xD;
&#xD;
          4. Severe comorbidities as measured by morbidity index.&#xD;
&#xD;
          5. Disease progression on first line systemic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yostena NK Mekhail, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eman AR Tawfeek, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enas AB Elkhouly, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reham A Abdel Aziz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed S Fathy</last_name>
    <role>Study Chair</role>
    <affiliation>Menoufia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yostena NK Mekhail, M.Sc</last_name>
    <phone>01061323285</phone>
    <phone_ext>+20</phone_ext>
    <email>yostena.mekhail@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medicine</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufia</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>faculty of medicine</last_name>
      <phone>0482330325</phone>
      <phone_ext>+20</phone_ext>
      <email>medcine@menofia.edu.eg</email>
    </contact>
    <contact_backup>
      <phone>0482224819</phone>
      <phone_ext>+20</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>yostena nagy kamel mekhail</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bronchogenic cancer</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>after publishing the primary results. and if further publications will be based on these data, should add us as co investigators.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>after publishing the primary results.</ipd_time_frame>
    <ipd_access_criteria>via mail contact to the primary investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

